# Clinical Trials Data ERBB2 - Document 47

# Biomarkers in Blood and Tissue Samples From Patients With Uterine Cancer

## Clinical Trial: https://clinicaltrials.gov/study/NCT01344837

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Women with uterine papillary serous carcinoma (UPSC) who were eligible for GOG-0210 protocol, a molecular staging study in endometrial cancer, or GOG-0136, a general specimen banking study for gynecologic cancer, have consented to future research, have histologically-confirmed UPSC of any stage, and have satisfactory formalin-fixed and paraffin-embedded primary tumor with or without a satisfactory pre-operative serum specimen available for testing\n\* Women with endometrioid endometrial cancer who were eligible for GOG-0210 or GOG-0136, have consented to future research, have histologically-confirmed endometrioid endometrial carcinoma with a similar stage, age and race/ethnicity distribution as the UPSC patients, have satisfactory formalin-fixed and paraffin-embedded primary tumor and/or pre-operative serum specimen available for testing\n\* Normal healthy control women who participated in the Biopathology protocol for banking sera from normal healthy control women, have consented to future research, do not have a cancer or a history of cancer and have a similar age and race/ethnicity distribution as the UPSC patients and have satisfactory serum available for testing",  
 "healthyVolunteers": false,  
 "sex": "FEMALE",  
"stdAges": [  
"CHILD",  
"ADULT",  
"OLDER\_ADULT"  
],  
 "studyPopulation": "Patients with uterine cancer",

Question:  
Based on the following clinical trial information, would a patient with a ERBB2 gene mutation be eligible for the clinical trial?

Answer:  
This trial focuses on uterine papillary serous carcinoma (UPSC) and endometrioid endometrial cancer. The eligibility criteria mention nothing about specific gene mutations, including ERBB2. Therefore, having an ERBB2 mutation doesn't automatically qualify or disqualify a patient. They would still need to meet the other inclusion criteria related to their specific uterine cancer type, prior study participation (GOG-0210 or GOG-0136), and sample availability.